Evidence Hub

MP79-06 compliance of dapoxetine in patients with premature ejaculation: a 2-year prospective observational study

Hyun Jun Park

The Journal of Urology, 2023

182 participants

Abstract

You have accessJournal of UrologyCME1 Apr 2023MP79-06 COMPLIANCE OF DAPOXETINE IN PATIENTS WITH PREMATURE EJACULATION: A 2-YEAR PROSPECTIVE OBSERVATIONAL STUDY Hyun Jun Park Hyun Jun ParkHyun Jun Park More articles by this author View All Author Informationhttps://doi.org/10.1097/JU.0000000000003356.06AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract INTRODUCTION AND OBJECTIVE: Although dapoxetine is the only oral pharmacological agent approved for the treatment of premature ejaculation (PE), and is very effective, the discontinuation rate is high. We assessed the discontinuation rate in patients with PE, and the reasons for discontinuation, in real-world practice. METHODS: A total of 182 consecutive patients were enrolled. The type of PE, the self-estimated intravaginal ejaculation latency time (IELT), and medical history were evaluated in all patients, who also completed the International Index of Erectile Function-Erectile Function Domain (IIEF-EFD) questionnaire. Visits were scheduled 1, 3, 6, 12, and 24 months after initiation of therapy; we checked treatment status and the reasons for discontinuation in those who did in fact discontinue. We compared the relationships of discontinuation rates with various parameters and the time to discontinuation after treatment commencement. RESULTS: Of all patients, 9.9% continued treatment to 2 years. The cumulative discontinuation rates at 1, 3, 6, 12, and…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free